乌苯美司联合卡培他滨治疗晚期老年结直肠癌临床观察

目的观察乌苯美司联合卡培他滨治疗老年晚期结直肠癌临床疗效和对免疫功能的影响。方法选择晚期结直肠癌患者共52例,随机分为治疗组26例和对照组26例。对照组采用卡培他滨进行治疗,治疗组在对照组的基础上加用乌苯美司片,连续治疗8周。结果有效率治疗组为34.6%,对照组为11.5%,两组比较,差异有统计学意义（P〈0.05）;治疗组T辅助淋巴细胞（CD3＋、CD4＋）增加,而对照组减少,差异有统计学意义（P〈0.05）;治疗组KPS评分稳定率高于对照组,体重稳定,差异有统计学意义（P〈0.05）,两组胃肠道反应、手足综合征及血液学毒性方面比较差异无统计学意义（P〉0.05）。结论乌苯美司联合卡培他滨可提高晚期结直肠癌患者临床疗效及免疫功能,改善患者生活质量。

Clinical observation on ubenimex plus capecitabine in treatment of elderly patients with advanced colorectal cancer

Objective To investigate the clinical curative effect of ubenimex combined with capecitabine in the treatment of advanced colorectal cancer and the effect on immune function. Methods A total of 52 cases of patients with advanced colorectal cancer,were randomly divided into treatment group 26 cases and control group of 26 cases. The control group applied capecitabine. The treatment group based on the control group was combined with ubenimex Tablets,continuous treatment for eight weeks. Results The effiective rate was 34. 6% in the treatment group,11. 5% in the control group. The difference was statistically significan between the two groups,（P 〈0. 05）. T assisted- induced lymphocytes（CD3 ＋,CD4 ＋） in the treatment group increased while decreasing in the control group. The difference was statistically significant（P〈 0. 05）. KPS score and body weight were stable in the treatment group. The difference was statistically significant（P〈 0. 05）. There was no significant difference between the two groups in gastrointestinal,hand-foot syndrorne and hematologic toxicity（ P 〉0. 05）. Conclusion Ubenimex combined with capecitabine can improve the clinical efficiency and immunefunction of advanced colorectal cancer patients,and improve the quality of life.